Association of Polymorphism in Cytochrome P450 2D6 and N-Acetyltransferase-2 with Parkinson's Disease. Issue 2 (2nd June 2013)

• Record Type: Journal Article
• Authors: Singh, Madhu; Khanna, Vinay K.; Shukla, Rakesh; Parmar, Devendra
• Is Part Of: Disease markers. Volume 28:Issue 2(2010)
• Page Start: 87
• Page End: 93
• Publication Date: 2013-06-02
• Subjects: Cytochrome P450 2D6 -- N-acetyltransferase-2 -- poor metabolizers -- parkinson disease -- risk; Diagnosis -- Periodicals; Biochemical markers -- Periodicals; Pathology -- Periodicals; 616
• DOI: 10.3233/DMA-2010-0688
• Languages: English
• ISSNs: 0278-0240

Abstract

Abstract : The present case-control study was carried out to investigate the association of polymorphism in cytochrome P450 2D6 ( CYP2D6 ) and N-acteyltransferase-2 ( NAT2 ), that are involved in the metabolism and detoxification of chemicals causing Parkinson disease (PD) like symptoms, with PD. Our data demonstrated increased frequency of CYP2D6*2 (1749G/C and 2938C/T), CYP2D6*4 (1934G/A) and CYP2D6*10A (188C/T) polymorphisms in PD cases when compared to the controls. Statistical analysis revealed the significant association of CYP2D6*4 (1934G/A) and CYP2D6*10A (188C/T) polymorphism with PD. Likewise, increased frequency of NAT2*7 polymorphism that leads to the slow acetylator phenotype was observed in PD patients with more than fivefold increased risk (OR: 5.55; 95%CI: 0.56–54). No change was observed in the frequency of NAT*5 or NAT*6 alleles in the cases. Further, cases carrying combination of heterozygous genotypes of CYP2D6*4 or CYP2D6*10A ( 188C > T ) and NAT2*5 were found to be at significantly higher risk for PD demonstrating the importance of gene-gene interactions in determining susceptibility to PD.